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Eps15Ebola virus (EBOV) infects several cell types and while viral entry is known to be pH-dependent, the exact
entry pathway(s) remains unknown. To gain insights into EBOV entry, the role of several inhibitors of
clathrin-mediated endocytosis in blocking infection mediated by HIV pseudotyped with the EBOV envelope
glycoprotein (EbGP) was examined. Wild type HIV and envelope-minus HIV pseudotyped with Vesicular
Stomatitis Virus glycoprotein (VSVg) were used as controls to assess cell viability after inhibiting clathrin
pathway. Inhibition of clathrin pathway using dominant-negative Eps15, siRNA-mediated knockdown of
clathrin heavy chain, chlorpromazine and sucrose blocked EbGP pseudotyped HIV infection. Also, both
chlorpromazine and Baﬁlomycin A1 inhibited entry of infectious EBOV. Sensitivity of EbGP pseudotyped HIV
as well as infectious EBOV to inhibitors of clathrin suggests that EBOV uses clathrin-mediated endocytosis as
an entry pathway. Furthermore, since chlorpromazine inhibits EBOV infection, novel therapeutic modalities
could be designed based on this lead compound.cular Biology, Feinberg School
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Ebola virus (EBOV) causes a severe, fatal hemorrhagic fever with
mortality rates as high as 90% (Feldmann et al., 2003). There is
currently no effective anti-viral therapy available for EBOV infection.
EBOV is an enveloped, negative-sense, single stranded RNA virus
(Regnery et al., 1980) with a broad species and cell-type tropism
(Wool-Lewis and Bates, 1998). The envelope glycoprotein (GP) is
responsible for entry (Elliott et al., 1985). Very little is known about
the pathway used by EBOV to enter target cells and its receptor(s)
remains unidentiﬁed. It is known that EBOV entry in the context of
pseudotypes is pH-dependent (Chazal et al., 2001). Depletion of
membrane cholesterol by β-methyl cyclodextrin inhibits EBOV
infection in a dose dependent manner (Yonezawa et al., 2005; Bavari
et al., 2002). There have been conﬂicting reports on the endocytic
pathway(s) used by EBOV to enter target cells. One group suggested
that Ebola enters cells via caveolar uptake (Empig and Goldsmith,
2002) and uses the folate receptor alpha as a cofactor for EbGPmediated fusion (Chan et al., 2001). Another study has suggested that
EBOV uses clathrin as well as caveolae-mediated endocytosis for entry
using various chemical inhibitors of these pathways (Sanchez, 2007).
However, most of the inhibitors caused considerable cell detachment
in this study and it was conducted only in Vero cells so cell-type
speciﬁc effects could not be ruled out. In contrast, two reports had
previously shown that neither caveolae nor folate receptor alpha are
required for EbGP fusion function (Simmons et al., 2003; Sinn et al.,
2003). In light of these controversies more analysis is required.
The major endocytic pathways include clathrin-mediated endo-
cytosis, uptake by caveolae, macropinocytosis and phagocytosis. Some
non-clathrin (Nemerow and Cooper, 1984), non-caveolae-mediated
viral endocytic pathways have also been reported (Sanchez-San
Martin et al., 2004) but they are not well described.
Among all the known pathways of viral endocytosis, clathrin-
mediated endocytosis is predominant. Key proteins involved in
clathrin-mediated endocytosis include clathrin, Adaptor Protein
Complex-2 (AP-2) and epidermal growth factor receptor (EGFR)
pathway substrate clone 15 (Eps15). Clathrin assembles into a
polyhedral lattice on the inner side of the plasma membrane to form
the coated pit. Eps15 acts as an adaptor between the clathrin coats
and AP-2 (Keen, 1987). An AP-2 independent pathway for clathrin-
mediated endocytosis has also been reported (Lakadamyali et al.,
2006). Eps15 comprises of three structural domains: an N-terminal
region (DI) composed of three Eps15 homology regions, a central
coiled-coil domain (DII) involved in oligomerization and a C-terminal
region (DIII) which contains the AP-2 binding sites. DI is required for
Fig. 1. Importance of acidiﬁcation on EbGP mediated entry. Infectivity of EbGP, VSVg
pseudotyped virus and HIV on HOS cells in the presence or absence of 50 nM
Baﬁlomycin A1 (Baf A1). Error bars represent SEM for three independent infection
samples. *p Value for EbGP=0.0003 (extremely signiﬁcant) and p value for
VSVg=0.0003 (extremely signiﬁcant).
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expressing mutants lacking Eps15 homology domains, punctate
distribution of AP-2 and clathrin is lost and endocytosis of transferrin,
which is a speciﬁc marker of clathrin-mediated endocytosis (Hanover
et al., 1984) is inhibited (Benmerah et al., 1999). Certain chemical
agents such as chlorpromazine (Wang et al., 1993) and sucrose
(Heuser and Anderson, 1989) are also known to prevent recycling of
clathrin to the plasma membrane thereby inhibiting clathrin-mediat-
ed endocytosis.
In this study we examined whether EBOV requires the clathrin-
mediated endocytic pathway for entry. Our results demonstrate
that EbGP pseudotyped HIV as well as replication-competent EBOV
use clathrin-mediated endocytosis as an entry pathway. We have
also shown that chlorpromazine signiﬁcantly inhibits replication-
competent EBOV infection and hence is a potential lead candidate for
development of anti-viral therapy against EBOV infection.
Results
EbGP mediated entry of the HIV pseudotype is pH-dependent
To analyze the pathway of Ebola virus entry, we used an envelope-
minus HIV pseudotyped with the Ebola virus envelope glycoprotein
(EbGP). For this analysis we utilized two control viruses, HIV using its
native envelope and envelope-minus HIV pseudotyped with VSVg.
HIV entry is pH-independent (Stein et al., 1987), while entry
mediated by VSVg pseudotyped HIV is pH-dependent (Matlin et al.,
1982). The control viruses were used to demonstrate target cell
viability and speciﬁcity of the inhibitory disruption of the clathrin
pathway. In all cases, the viral genomes contained the GFP gene
located in the Nef position within the HIV genome. Therefore, infected
cells could be readily identiﬁed for GFP expression using ﬂow
cytometry or microscopy. The initial analysis was designed to conﬁrm
the previously reported role of acidiﬁcation in the function of EbGP,
VSVg and HIV envelopes. Vacuolar ATPases hydrolyze ATP, creating a
proton gradient that causes acidiﬁcation of endosomes. Baﬁlomycin
A1 (Baf A1) is a potent inhibitor of vacuolar ATPases and thereby
prevents acidiﬁcation of endosomes (Bowman et al., 1988). For this
analysis, the titer of the different viral stocks was determined using
infectivity studies. In this study, the different stocks were added at
amounts that gave comparable levels of infectivity. When normalized
by p24 content, the VSVg pseudotyped virus was typically 25 times
more infectious than replication-competent HIV and 79 times more
infectious than the EbGP pseudotyped HIV after 4 h of exposure to
target cells.
Baf A1 treatment reduced both EbGP and VSVg mediated infec-
tivity to near background levels, while HIV infectivity showed a minor
increase compared to the untreated control (Fig. 1). These results
validated the functionality of the pseudotyping system and infectivity
assays since a previous study has also reported that treatment
with Baf A1 signiﬁcantly inhibited EbGP and VSVg pseudotyped viral
infection, while enhancing HIV infection (Chazal et al., 2001).
Inhibition of EbGP mediated entry by chlorpromazine
To investigate the potential role of clathrin-mediated endocytosis,
we ﬁrst determined the ability of the drug chlorpromazine to inhibit
EbGP mediated viral entry. Chlorpromazine is known to sequester
clathrin, causing it to assemble aroundendosomalmembranes thereby
preventing recycling of clathrin to the plasmamembrane (Wang et al.,
1993). A previous study used 10 μg/ml of chlorpromazine to
determine the involvement of clathrin pathway in inﬂuenza virus
entry (Sieczkarski and Whittaker, 2002).
To determine the effect of chlorpromazine treatment on clathrin
localization, cells were transiently transfected with eGFP-clathrin.
After 24 h, the cells were treated with 10 μg/ml of chlorpromazinefor 45 min, ﬁxed and analyzed by ﬂuorescent deconvolution mi-
croscopy. In the treated cells, clathrin was seen in random clusters
in the cytoplasm, while in the untreated cells, a distinct punctate
distribution of clathrin was seen throughout the cell (Fig. 2A). To
determine the functional consequences of chlorpromazine treat-
ment, we examined if the endocytosis of transferrin, a known
marker for clathrin-mediated endocytosis (Hanover et al., 1984),
was altered. Fluorescently labeled transferrin was added to HOS
cells either pre-treated with 10 μg/ml chlorpromazine for 2 h or
untreated. After 5 min of incubation, the cells were rinsed to remove
any unbound transferrin and ﬁxed for ﬂuorescent deconvolution
microscopy analysis. As shown in Fig. 2B, ﬂuorescent transferrin
was localized in a perinuclear compartment, most likely recycling
endosomes, in untreated cells. In contrast, no internalized trans-
ferrin was detected in the chlorpromazine treated cells. These
studies demonstrate that 10 µg/ml chlorpromazine potently inhibits
clathrin-mediated endocytosis. We also examined the effect of
chlorpromazine on the recycling of transferrin receptor and found
that transferrin receptor is predominantly localized in the peri-
nuclear region following treatment with chlorpromazine (Fig. 2C),
while in the untreated cells, transferrin receptor is uniformly dis-
tributed all over the cell. This result explained the absence of any
transferrin on the cell surface after chlorpromazine treatment in
Fig. 2B.
Next, we determined the effect of chlorpromazine treatment on
infection mediated by the EbGP, VSVg and HIV envelopes in HOS cells.
As seen in Fig. 2D, treatment with 10 µg/ml chlorpromazine potently
inhibited EbGP pseudotyped HIV infection without having any effect
on infection with either wt HIV or VSVg pseudotyped HIV. The normal
infectivity by wt HIV and VSVg pseudotyped HIV demonstrated that
the chlorpromazine treatment was not toxic to the target cells. The
effect of chlorpromazine on EbGPmediated infectivity was also tested
in HeLa, Vero, 293T and HMEC cell lines to determine whether the
effect was cell-type speciﬁc for HOS cells or could be seen in other cell
types including endothelial cells, which are one of the target cells for
ﬁloviral infection. Chlorpromazine severely inhibited EbGP mediated
infectivity in HMEC (Fig. 2E) and also HeLa, Vero and 293T cells
(Fig. 2F), which suggests that inhibition of EbGP mediated infectivity
by chlorpromazine is not restricted to a certain cell type but is
prevalent among different cell types. The inhibitory effect of
chlorpromazine on EbGP mediated infectivity was found to be dose
dependent for doses of 10 μg/ml or lower with maximum inhibitory
effect seen at 10 μg/ml (Fig. 2G).
Fig. 2. Chlorpromazine (CPZ) strongly inhibits EbGP mediated viral infection. (A) Transfection of HOS cells with eGFP-clathrin followed by treatment with 10 μg/ml chlorpromazine
for 45 min. The left panel shows an untreated cell while the right panel shows a chlorpromazine treated cell. Scale bars represent 15 μm. (B) Treatment of HOS cells with 10 μg/ml
chlorpromazine for 2 h followed by incubation with 14 μg/ml of TR-transferrin for 5 min. The image on the left represents untreated cells, while the image on the right depicts
chlorpromazine treated cells. Scale bars represent 15 μm. (C) Treatment of HOS cells with 10 μg/ml chlorpromazine for 45 min followed by ﬁxing and staining for transferrin
receptor usingmousemonoclonal antibody against human transferrin receptor and Cy3-conjugated anti-mouse secondary antibody. The image on the left represents untreated cells,
while the image on the right depicts chlorpromazine treated cells. Scale bars represent 30 μm. (D) Infectivity of EbGP, VSVg pseudotyped virus and HIV on HOS cells wasmeasured in
the presence or absence of 10 μg/ml chlorpromazine. Error bars represent SEM for three independent infection samples. *p Value=0.0449 (signiﬁcant). (E) Infectivity of EbGP
pseudotyped virus on HMEC cells was measured in the presence or absence of 10 μg/ml chlorpromazine. Error bars represent SEM for three independent infection samples.
*p Value=0.0009 (extremely signiﬁcant). (F) Comparison of infectivity of EbGP pseudotyped virus in HOS, HeLa, Vero and 293T cells measured in the presence or absence of 10 μg/
ml chlorpromazine. Error bars represent SEM for three independent infection samples. *p Value for HOS=0.0071 (very signiﬁcant), p value for HeLa=0.0017 (very signiﬁcant), p
value for Vero=0.0037 (very signiﬁcant) and p value for 293T=0.0001 (extremely signiﬁcant). (G) XY plot depicting dose response effect of chlorpromazine treatment on EbGP
mediated infectivity in HOS cells. # represents complete cytotoxicity meaning no cells were left on the plate.
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To further explore the observed involvement of clathrin-mediated
endocytosis on entry mediated by EbGP, we inhibited clathrin-
mediated endocytosis using 0.45 M sucrose. A previous study has
shown that treatment with 0.45 M sucrose led to formation of clathrin
microcages on the inner surface of the plasma membrane thereby
depleting the cytoplasmic pools of clathrin necessary for normal
coated pit formation (Heuser and Anderson, 1989).
When cells were transfected with eGFP-clathrin followed by
treatment with 0.45 M sucrose for 10 min, there was an increased
accumulation of clathrin in the perinuclear region, while in untreatedcells, clathrin exhibited a uniform punctate distribution throughout
the cell (Fig. 3A). An increased accumulation of clathrin in the
perinuclear region has been previously reported in sucrose treated
cells (Heuser and Anderson, 1989). Next, we determined the
functional consequences of sucrose treatment on clathrin-mediated
endocytosis. For this, we determined the ability of sucrose treatment
to inhibit the internalization of ﬂuorescently labeled transferrin. Pre-
treatment of HOS cells with 0.45 M sucrose for 45 min inhibited entry
of TR-transferrin, whereas in untreated cells, transferrin was
endocytosed within 5 min (Fig. 3B). The effect of sucrose treatment
on recycling of transferrin receptor was also examined and it was
found that sucrose causes accumulation of transferrin receptor in the
Fig. 3. EbGPmediated viral infection is inhibited by sucrose. (A) Transient transfection of HOS cells with eGFP-clathrin followed by treatment with 0.45 M sucrose for 10 min. The left
panel shows an untreated cell, while the right panel shows sucrose treated cells. Scale bars represent 15 μm. (B) Treatment of HOS cells with 0.45 M sucrose for 45 min followed by
incubation with 14 μg/ml of TR-transferrin for 5 min. The image on the left represents untreated cells, while the image on the right shows sucrose treated cells. Scale bars represent
15 μm. (C) Treatment of HOS cells with 0.45 M sucrose for 10 min followed by ﬁxing and staining for transferrin receptor using mouse monoclonal antibody against human
transferrin receptor and Cy3-conjugated anti-mouse secondary antibody. The image on the left represents untreated cells, while the image on the right depicts sucrose treated cells.
Scale bars represent 30 μm. (D) Infectivity of EbGP, VSVg pseudotyped virus and HIV on HOS cells was measured in the presence or absence of 0.45 M sucrose. Error bars represent
SEM for three independent infection samples. *p Value=0.0047 (very signiﬁcant). (E) Infectivity of EbGP pseudotyped virus on HMEC cells measured in the presence or absence of
0.45 M sucrose. Error bars represent SEM for three independent infection samples. *p Value=0.0001 (extremely signiﬁcant). (F) Comparison of infectivity of EbGP pseudotyped
virus on HOS, HeLa, Vero and 293T cells measured in the presence or absence of 0.45 M sucrose. Error bars represent SEM for three independent infection samples. *p Value for
HOS=0.0091 (very signiﬁcant), p value for HeLa=0.0018 (very signiﬁcant), p value for Vero=0.0014 (very signiﬁcant) and p value for 293T=0.0012 (very signiﬁcant). (G) Effect
of combination of chlorpromazine and sucrose on viral entry. Viral infectivity was measured following pre-treatment with a combination of 10 μg/ml chlorpromazine and 0.45 M
sucrose for 45 min. Error bars represent SEM for three independent infection samples. *p Value for EbGP=0.0125 (signiﬁcant) and p value for HIV=0.0309 (signiﬁcant).
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present on the cell surface upon sucrose treatment in Fig. 3B.
Next, we determined the effect of sucrose treatment on infection
mediated by the EbGP, VSVg, and HIV envelopes. A potent decrease in
EbGPmediated infectivity was observed in sucrose treated cells, while
VSVg and HIV infectivity remained unaffected when compared to
untreated controls (Fig. 3D). Since VSVg and HIV infectivity were
unaltered, it suggests that the sucrose treatment was not toxic to
the cells. Furthermore, we investigated the effect of sucrose treatment
on EbGP mediated infectivity in HMEC cells and as seen in Fig. 3E,
sucrose severely inhibited EbGP mediated infectivity in endothelialcells, which are one of the target cells of ﬁloviral infection. We also
compared the effect of sucrose treatment on EbGP mediated infec-
tivity in HOS, HeLa, Vero and 293T cells and as seen in Fig. 3F, sucrose
signiﬁcantly inhibited EbGP mediated infectivity in all these cell lines
indicating that the inhibitory effect of sucrose was not restricted to
HOS cells.
One surprising observation was that VSVg pseudotyped viral
infection was not inhibited by either chlorpromazine or sucrose
treatment since it has been previously reported that VSV entry
is mediated by clathrin-mediated endocytosis (Sun et al., 2005).
To further investigate this process, we evaluated a combination
22 S. Bhattacharyya et al. / Virology 401 (2010) 18–28treatment with chlorpromazine and sucrose. Treatment with a com-
bination of 10 μg/ml chlorpromazine and 0.45 M sucrose caused a
relocalization of eGFP-clathrin to a perinuclear region and inhibited
the endocytosis of ﬂuorescently labeled transferrin (data not shown).
In cells treated with a combination of 10 μg/ml chlorpromazine and
0.45 M sucrose, EbGPmediated infectivity was reduced to background
levels; VSVg infectivity remained unchanged, while HIV infectivity
was increased in treated cells when compared to untreated controls
(Fig. 3G). We also examined the effect of increasing concentrations
of chlorpromazine on VSVg mediated infectivity in HOS cells and
found that concentrations between 50 μg/ml and 150 μg/ml were
completely cytotoxic, while 10 μg/ml or lower concentrations did not
have any effect on infectivity (data not shown).
EbGP mediated entry is inhibited by expression of dominant-negative
Eps15
Having established the effect of two chemical inhibitors of
clathrin-mediated endocytosis in inhibiting EbGP mediated entry,
we next examined the effect of a molecular inhibitor of the clathrin
pathway to see if it could also block EbGP mediated entry. For this, we
transfected HOS cells with a dominant-negative Eps15, DIII, which has
deletion of all three Eps15 homology domains (Benmerah et al., 2000)
or a control Eps15 plasmid D3Δ2, which is a 760 nucleotide insert
analogous to DIII but lacking the AP-2 binding sites (Benmerah et al.,
2000). First, we examined the functional effect of these constructs
on transferrin endocytosis and found that in cells transfected with
mRFP-DIII, transferrin entry was completely inhibited, while in D3Δ2Fig. 4. Dominant-negative Eps15 inhibits EbGP mediated viral entry. (A) Transfection of H
negative (DN) Eps15 plasmid (right panel) followed by incubation with Fluorescein–transfe
cells, green represents transferrin and blue represents nuclei. Arrows indicate transferri
untransfected cells. Scale bar represents 30 μm. (B) Fold decrease in viral infectivity in HOS ce
bars represent SEM for three independent experiments. *p Value for fold change in EbGP m
(C) Comparison of fold decrease in EbGP mediated infectivity in HeLa, 293T and Vero cells tra
represent SEM for three independent experiments. Typically, there were 20–30% transfecte
plasmid and infected with EbGP virus in all four cell lines.transfected cells, transferrin was endocytosed at similar levels
compared to adjoining untransfected cells (Fig. 4A).
Next, we examined the effect of dominant-negative and control
Eps15 on viral entry mediated by EbGP, VSVg and wt HIV. There was a
greater than 5-fold decrease in EbGP mediated infectivity in cells
transfected with dominant-negative DIII plasmid when compared to
cells transfected with the D3Δ2 control plasmid over three indepen-
dent experiments, while VSVg and HIV infectivity levels were com-
parable in cells transfected with DIII or D3Δ2 plasmids (Fig. 4B). This
result conﬁrmed that EbGP facilitates infection via clathrin-mediated
endocytosis. Further, we compared the role of Eps15 in EbGP medi-
ated infectivity in HeLa, 293T and Vero cells and as seen in Fig. 4C,
there was a considerable inhibition of EbGP mediated infectivity in all
three cell types transfected with dominant-negative Eps15 when
compared to cells transfected with control Eps15.
siRNA-mediated knockdown of clathrin inhibits EbGP mediated viral
infectivity
In order to further conﬁrm the involvement of clathrin in EbGP
mediated viral infectivity, we compared the effect of knockdown of
clathrin heavy chain on EbGP and VSVg pseudotyped virus and
wt HIV entry in HOS cells. We used a previously well characterized
siRNA duplex (Huang et al., 2004), which was shown to speciﬁcally
knockdown clathrin by 90–95% in HeLa cells without causing any off-
target effects.
First, we performed a functional study to examine transferrin
endocytosis upon clathrin knockdown. For this, HOS cells wereOS cells with mRFP-D3Δ2 control Eps15 plasmid (left panel) or mRFP-DIII dominant-
rrin for 30 min. The nuclei were stained with Hoechst. Red represents Eps15 transfected
n endocytosis in the D3Δ2 control Eps15 cells, which is comparable to neighboring
lls transfected with DIII DN Eps15when compared to D3Δ2 control Eps15 plasmid. Error
ediated infectivity compared to VSVg and HIV infectivity=0.0021 (very signiﬁcant).
nsfected with DIII DN Eps15 when compared to D3Δ2 control Eps15 plasmid. Error bars
d and infected cells (double positive cells) in cells transfected with the D3Δ2 control
23S. Bhattacharyya et al. / Virology 401 (2010) 18–28transiently co-transfected with siRNA against clathrin heavy chain
and eGFP plasmid (as a transfection marker) followed by incubation
with TR-transferrin for 30 min. In the siRNA-transfected cells, trans-
ferrin entry was severely inhibited in cells expressing eGFP and these
cells also showed very low levels of clathrin thereby conﬁrming
efﬁcient knockdown of clathrin (Fig. 5A). In contrast, transferrin
was endocytosed in cells where clathrin expression was not down-
regulated (cells not expressing eGFP). The efﬁciency of clathrin
knockdown was further conﬁrmed by western blotting, which
showed a protein band of approximately 180 kD representing theFig. 5. EbGP mediated viral infection is inhibited by siRNA-mediated knockdown of clathrin
heavy chain. (A) Co-transfection of HOS cells with eGFP and siRNA against clathrin heavy
chain followedby incubationwith14 μg/ml of TR-transferrin for 30 min. Cellswereﬁxed and
stained for clathrin (shown in blue) usingmousemonoclonal antibody against clathrin heavy
chain and Cy5-conjugated anti-mouse secondary antibody. Arrows indicate transferrin
endocytosis in the neighboring untransfected cells. Scale bar represents 15 μm. The side
panels show individual channels in a single siRNA-transfected cell (co-transfectedwith eGFP)
and demonstrate that there is very little clathrin and no internalized transferrin in that eGFP-
expressing cell. (B) HOS cells in 12 well plates were transfected twice with siRNA against
clathrin followed by western blot detection of clathrin using mouse monoclonal antibody
against clathrin heavy chain. GAPDH was measured as a loading control. (C) HOS cells on
coverslips were transfected twice with siRNA against clathrin heavy chain and mCherry
plasmid as a transfectionmarker. Control cellswere transfectedwithmCherry plasmid alone.
48 h following the second transfection, the cells were incubatedwith virus for 4 h. 48 h post-
infection, the cellswereﬁxedand theDNAwas stainedwithHoechst. Severalpanels of images
were collected from each sample and the number of transfected cells and transfected and
infected cells were counted in each panel. Graph represents the fold decrease in viral
infectivity in siRNA-transfected cells when compared to control cells. Error bars represent
SEMfor three independentexperiments. *pValue for fold change inEbGPmediated infectivity
compared to VSVg andHIV infectivity=0.0006 (extremely signiﬁcant). Typically, therewere
20% transfected and infected cells (double positive cells) in control cells infected with EbGP
virus and 25% transfected and infected cells in siRNA-treated as well as control cells for VSVg
and HIV infection.clathrin heavy chain in the control sample, while therewas no clathrin
protein detected in the siRNA sample (Fig. 5B). The blots were also
probed for GAPDH as a loading control and similar amounts of GAPDH
were detected in the siRNA-treated and control samples.
Next, we determined viral infectivity following siRNA-mediated
knockdown of clathrin. For this, we co-transfected HOS cells with
the siRNA against clathrin heavy chain and mCherry plasmid (as a
transfection marker) followed by infection with EbGP, VSVg and
replication-competent HIV GFP reporter viruses. Control cells were
transfected with mCherry plasmid alone. The total number of trans-
fected alone and transfected and infected cells was counted in each
population after imaging several panels of cells from each coverslip.
As seen in Fig. 5C, there was a 4.8 fold decrease in EbGP mediated
infectivity in cells transfected with siRNA against clathrin when
compared to control cells. VSVg and wt HIV infectivity remained
unchanged in siRNA-transfected versus control cells. This result fur-
ther conﬁrmed that entry mediated by EbGP is clathrin dependent.
Baﬁlomycin A1 and chlorpromazine inhibit infection by
replication-competent Ebola virus
Given the signiﬁcant difference in the morphology of the EbGP
pseudotyped HIV and the authentic Ebola virus, it was important
to verify the results of the experiments with EbGP pseudotyped
HIV in the context of real EBOV infection. For this purpose, we used a
recombinant virus ZEBOV-GFP in which the GFP gene has been
inserted downstream of the gene for Ebola nucleoprotein (NP)
(Towner et al., 2005). Infection of cells with this virus can be
monitored by visualization of GFP expression using microscopy or
ﬂow cytometry.
First, we examined if infectious EBOV entry requires acidiﬁcation
of endosomes. For this, Vero E6 cells plated in triplicate in a 96 well
plate were treated with or without Baf A1 for 2 h followed by addition
of ZEBOV-GFP at an MOI of 1. Cells were incubated with the virus for
1 h then washed to remove the excess virus and the medium without
drug was replenished. After 48 h, the cells were ﬁxed on the plate,
nuclei were stained with Hoechst and the percentage of infected cells
was determined with a Discovery 1 screening device. As shown
in Fig. 6A, 10 nM Baf A1 effectively blocked EBOV entry. This data
supports the ﬁndings with the pseudotyped virus system that acid-
iﬁcation of endosomes is required for the entry of infectious EBOV.
Next, we examined the effect of chlorpromazine on ZEBOV-GFP
infection of Vero-E6 cells in a similar fashion as the above experiment,
with the exception that the drug was kept in the culture for the entire
incubation period. To ensure lack of cytotoxicity, we ﬁrst treated cells
with increasing concentrations of chlorpromazine for 48 h and mea-
sured cell viability by Sytox green exclusion assay using the Discovery
1 microscope. No signiﬁcant cytotoxicity was observed at concentra-
tions up to 10 μg/ml whereas 30–40% decline in viability was
observed at 20 μg/ml (Fig. 6B). We then examined the effect of
chlorpromazine on infection of ZEBOV-GFP. As shown in Fig. 6C,
chlorpromazine caused a dose dependent inhibition of EBOV infection
with almost complete inhibition at 10 μg/ml. Representative images
from untreated and drug treated cells are shown in Fig. 6D. Next, we
examined the effect of various concentrations of chlorpromazine on
ZEBOV-GFP infectivity in HeLa cells and similar to Vero-E6 cells, there
was a dose dependent decline and viral infectivity dropped to
background level at 10 μg/ml concentration (Fig. 6E). This data
indicated that the inhibitory effect of chlorpromazine on EBOV
infectivity was not restricted to Vero-E6 cells. Since chlorpromazine
was shown to block entry of transferrin, which is a known marker for
clathrin-mediated endocytosis, inhibition of ZEBOV-GFP infection
following treatment with chlorpromazine in Vero-E6 and HeLa cells
supports the results seen with EbGP pseudotyped virus to demon-
strate that Ebola virus uses clathrin-mediated endocytosis as an entry
pathway.
Fig. 6. Baf A1 and chlorpromazine inhibit replication-competent EBOV infection. (A) Vero E6 cells were seeded in 96 well plates and pre-treated with 10 nM Baf A1 before infection
with ZEBOV-GFP. After 1 h attachment of virus, cells were washed and incubated with medium alone for 48 h, and were ﬁxed and the infected cells visualized and quantiﬁed by
Discovery 1 microscope for 9 regions per well. Error bars represent SEM for three independent infection samples. *p Value=0.0028 (very signiﬁcant). (B) Effect of chlorpromazine
on viability of Vero E6 cells. Cells were treated with increasing concentrations of chlorpromazine for 48 h and cell viability was measured by Sytox green staining and quantiﬁcation
of cells using Discovery 1 microscope. (C) Vero cells were plated in 96 well plates and treated with different concentrations of chlorpromazine and infected with ZEBOV-GFP at an
MOI of 1. After virus attachment and washing the excess virus, media containing the same concentrations of drug were replenished. After 48 h, the cells were ﬁxed and percent
infection determined using Discovery 1 microscope for 9 regions per well. Error bars represent SEM for three independent infection samples. (D) Images captured with Discovery 1
microscope from infected cells treated with medium alone (upper panel) or 10 μg/ml chlorpromazine (lower panel). Green represents infected cells and blue represents nuclear
staining with Hoechst. Scale bar represents 50 μm. (E) HeLa cells were treated with different concentrations of chlorpromazine and infected with ZEBOV-GFP as described above in
(C). 48 h later, the cells were ﬁxed and percent infection was determined using Discovery 1 microscope for 9 regions per well. Error bars represent SEM for three independent
infection samples.
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In this study, we present two lines of investigation that reveal that
EBOV utilizes the clathrin-mediated endocytic pathway to infect cells.
First, using envelope-minus HIV pseudotyped with EbGP, we ﬁnd that
viral infection is blocked by chemical and dominant-negative inhib-
itors of clathrin endocytic pathway. Likewise, siRNA-mediated knock-
down of clathrin heavy chain also inhibited infection with EbGP
pseudotyped HIV. Importantly, the inhibition of clathrin-mediated
endocytosis was speciﬁc because chlorpromazine, sucrose, dominant-
negative Eps15 and siRNA-mediated knockdown of clathrin had
no inhibitory effect on infection mediated by either VSVg or HIV
envelope. This speciﬁcity demonstrated that the inhibition of clathrin-mediated endocytosis was not cytotoxic. Secondly, chlorpromazine
could potently inhibit infection with replication-competent EBOV.
These studies validate the results obtained with the HIV pseudotype
system and demonstrate that clathrin-mediated endocytosis is
necessary for infection with the ﬁlamentous particles characteristic
of the ﬁlovirus Ebola.
The potential role of clathrin-mediated endocytosis may seem
surprising when considering the known small and spherical nature of
clathrin coated pits. Typically, they are on the order of 120 nm
(Conner and Schmid, 2003). Ebola virus on the other hand has a
diameter of 80 nm, but is ﬁlamentous in nature. It has previously been
reported that maximal infectivity of EBOV is associated with ﬁla-
mentous particles 970 nm long and EBOV particles can reach up to
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reveals that clathrin-mediated endocytosis is not restricted to small
spherical coated pits. Listeria has been shown to utilize clathrin-
mediated endocytosis to enter cells (Veiga and Cossart, 2005). The
large size of the Listeria, which extends to 2 μm (Giardini and Theriot,
2001), suggests that clathrin coated pits should be able to readily
accommodate the ﬁlamentous particles of EBOV.
Inhibition of clathrin-mediated endocytosis was previously shown
to block wild type VSV infection (Sun et al., 2005). So a surprising
ﬁnding from our study is that infection mediated by VSVg pseudo-
typed HIV remained unaffected after disrupting the clathrin endocytic
pathway using four different approaches. However, VSVg infection
was inhibited by Baf A1, which agreed with the pH-dependence pre-
viously reported for VSVg pseudotyped viruses and wild type VSV
(Matlin et al., 1982). There could be several reasons why VSVg
mediated entry was unaffected by inhibitors of the clathrin pathway
in our study. Perhaps, there are differences in the context of wild type
virus compared to the function of VSVg in the context of pseudotyped
HIV. Alternatively, the use of certain entry pathways may be cell-type
dependent. For example, in the case of inﬂuenza virus it has been
shown that the virus can enter via several pathways including clathrin
(Rust et al., 2004), caveolae (Nunes-Correia et al., 2004) and a clathrin
and caveolae independent pathway (Sieczkarski andWhittaker, 2002;
Rust et al., 2004). Likewise, similar results have been reported for
adenovirus (Varga et al., 1991; Svensson, 1985; Yoshimura, 1985;
Meier et al., 2002). Therefore, past data and ﬁndings from this study
put together suggest that like inﬂuenza virus, VSV could perhaps use
multiple endocytic pathways for entry.
Like inﬂuenza virus and adenovirus, it is also possible that EBOV
could utilize other entry pathways in addition to clathrin-mediated
endocytosis under different circumstances. However, there appears
to be an important role for clathrin-mediated endocytosis in the
infection of HOS, HeLa, Vero, 293T and primary human endothelial
cells with EbGP pseudotypes and Vero and HeLa cells with replication-
competent EBOV as presented in this study.
Recent studies indicate that the viral endocytic pathways are not
as well deﬁned as was previously believed. Several studies have
shown that although some viruses such as HIV (Popik et al., 2002),
Vaccinia virus (Chung et al., 2005), Coxsackievirus (Triantaﬁlou
and Triantaﬁlou, 2003) and ﬁloviruses (Bavari et al., 2002) could
use lipid rafts as sites of entry and cholesterol depletion inhibits viral
entry, these viruses may not necessarily enter via caveolae-mediated
endocytosis. Moreover, some studies have shown that clathrin-
mediated endocytosis may occur in the absence of AP-2 (Lakadamyali
et al., 2006; Motley et al., 2003), which was initially considered to be a
critical adaptor for this pathway. These data indicate that although a
virus may use a certain pathway for entry, it could use proteins or
adaptors that are different from what have been previously described
as essential and hence the use of certain inhibitors of a pathway may
not necessarily block viral entry.
There are currently no therapeutic modalities available for EBOV
infection. It is intriguing that chlorpromazine was highly effective
in blocking EBOV infection. Chlorpromazine is a well-known psycho-
tropic drug approved by the Food and Drug Administration (Adams
et al., 2005), which has also been shown to possess antimicrobial
activities (Kristiansen and Mortensen, 1987). Our ﬁndings suggest
that this drug could be further investigated as a lead for chemoinfor-
matics-based design and development of a series of potential
inhibitors of EBOV replication. In this regard, it would be advanta-
geous to examine other phenothiazine derivatives with lower psy-
chotropic effects. Although chlorpromazine is shown to disrupt the
assembly of clathrin (Wang et al., 1993), the detailed mechanism of
action of chlorpromazine is not entirely understood. Chlorpromazine
is also known to inhibit calmodulin (Marshak et al., 1985; Wrenn
et al., 1981) and can bind to phospholipid components of the plasma
membrane of endothelial cells (Hueck et al., 2000). Therefore, itis possible that modulation of other cellular pathways may also
contribute to the inhibitory effect of chlorpromazine on EBOV
replication.
Using EbGP pseudotyped HIV as well as replication-competent
EBOV, the results of this study have provided extensive evidence
that EBOV uses clathrin-mediated endocytosis as an entry pathway.
Another novel observation is the abrogation of EBOV infection by
chlorpromazine, which could have important therapeutic implica-
tions. The role of chlorpromazine in inhibiting EBOV infection in
animal models is under investigation.
Materials and methods
Cell lines, plasmids and reagents
HEK293T, HOS-CD4, HeLa and Vero cells were maintained in
Dulbecco's modiﬁed Eagle medium (DMEM) supplemented with 10%
fetal bovine serum, penicillin–streptomycin–L-glutamine solution and
10 μg/ml ciproﬂoxacin. Human microvascular endothelial cells
(HMEC) were obtained from the American Type Culture Collection
(ATCC) and grown in MCDB131 medium (Gibco) supplemented with
0.7% FBS, 10 ng/ml EGF, 10 mM L-glutamine, 1 μg/ml hydrocortisone
and 50 U/ml penicillin–streptomycin.
The plasmid encoding Ebola Zaire GP (pCB6-EbGP) was obtained
from Dr. Paul Bates (Wool-Lewis and Bates, 1998). The VSVg and the
HIV provirus (R7ΔEnvGFP) vectors were obtained from the NIH AIDS
Research and Reference Reagent Program. The R73X4EnvGFP plasmid
was provided by Dr. Mark Muesing (Fisher et al., 1986). The eGFP-
clathrin plasmid was received from Dr. Lois Greene (Wu et al., 2001).
The GFP dominant-negative Eps15 (DIII) and GFP control Eps15
(D3Δ2) constructs were made by Alexandre Benmerah (Benmerah
et al., 1999) and received from Dr. John Young.
The GFP-Eps15 plasmids were digested with AgeI and BsrGI
restriction enzymes to remove the GFP fragment and mRFP was
inserted using the rapid ligation kit (Roche).
Polyethylenimine (PEI), Linear, MW 25,000 (Polysciences, Inc.)
was dissolved in distilled water to make 1 mg/ml stock solution.
Chlorpromazine hydrochloride (Sigma) and sucrose (Fisher) were
dissolved in distilled water to make 1 mg/ml and 5 M stock solutions
respectively. Baﬁlomycin A1 (Baf A1) (Sigma) was dissolved in DMSO
to make 20 μM stock solution. Texas Red (TR) and Fluorescein con-
jugated transferrin (Molecular Probes) were reconstituted to 5 mg/ml
solutions in phosphate-buffered saline (PBS). Mousemonoclonal anti-
human transferrin receptor antibody (Cat # 13-6800) was purchased
from Zymed Laboratories and Cy3 and Cy5 conjugated anti-mouse
secondary antibodies were purchased from Jackson ImmunoResearch
Laboratories, Inc.
Pseudotyped virus production
For preparing EbGP pseudotyped virus, HEK293T cells in a 15 cm
plate were transiently co-transfected with 20 μg of pCB6-EbGP and
30 μg of R7ΔEnvGFP HIV plasmids using 112 μl of PEI. 48 h post-
transfection, the supernatant was collected, centrifuged at 1500 rpm
for 5 min and clariﬁed by ﬁltration through a 0.45-μm pore-size ﬁlter.
VSVg pseudotyped GFP reporter virus was prepared similarly. For
making replication-competent HIV, the cells were transfected with
45 μg of R73X4EnvGFP plasmid. Viral content was measured using the
p24 ELISA kit (Perkin Elmer Lifesciences) according to the manufac-
turer's guidelines.
Infection with Ebola Zaire GFP virus and quantiﬁcation of infectivity
GFP-expressing replication-competent EBOV Zaire (ZEBOV-GFP)
was received from Dr. Jason Paragas (USAMRIID) (Towner et al.,
2005). Vero E6 and HeLa cells were plated on black-wall 96 well plates
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the wells 2 h prior to infection. Virus at indicated MOI was diluted in
EMEM medium and added to the wells. After 1 h attachment, the
excess virus was removed by washing twice with PBS and medium
containing the experimental compounds was added for the duration
of the culture. Cells were then ﬁxed by submerging the whole plate
in 10% neutral-buffered formalin for 3 days. The percentage of cells
expressing GFP and the average ﬂuorescence intensity of those cells
were measured with a Discovery-1 high content screening device
(Molecular Devices Corp., Downingtown, PA) for 9 regions per well.
These experiments were performed inside a Biosafety Level 4 (BSL-4)
laboratory.
Flow cytometric analysis to measure viral transduction following various
inhibitor treatments
HOS cells in 12 well plates were pre-treated with 50 nM Baf A1 for
30 min followed by overnight incubation with virus in the presence of
the drug. To block clathrin-mediated endocytosis, HOS, HeLa, Vero,
293T and HMEC cells in 12 well plates were pre-treated with either
0.45 M sucrose for 10 min or 10 μg/ml chlorpromazine for 45 min or a
combination of 10 μg/ml chlorpromazine and 0.45 M sucrose for
45 min. The cells were incubated with virus for 4 h in the presence
of the drug. After 4 h, the cells were washed extensively with PBS
followed by overnight incubation with the drug. Three independent
infection samples were analyzed for each virus. GFP ﬂuorescence (as a
marker of infectivity) was measured 48 h post-infection by ﬂow
cytometry using FACS Calibur (Becton Dickinson). Cells were gated on
forward and side scatter and the same gates were used for treated and
control samples. 10,000 gated events were accrued and analyzed for
each sample. Each experiment was repeated three times and similar
results were obtained each time. The data from one representative
experiment is shown in the ﬁgures.
Transfection with eGFP-clathrin followed by chlorpromazine or sucrose
treatment
HOS cells were plated on coverslips and transiently transfected
with eGFP-clathrin using Effectene transfection reagent (Qiagen) as
per the manufacturer's guidelines. 24 h post-transfection, cells were
treated with 0.45 M sucrose for 10 min or 10 μg/ml chlorpromazine
for 45 min or a combination of 10 μg/ml chlorpromazine and 0.45 M
sucrose for 45 min. Cells were ﬁxed with 3.7% formaldehyde
(Polysciences Inc.) in PIPES buffer (0.1 M PIPES (pH 6.8), 2 mM
MgCl2, and 1 mM EGTA). Cells were then rinsed with PBS and the DNA
was stained using Hoechst. Finally, the coverslips were mounted on
glass slides with Gel Mount (Biomeda) containing antifade agents.
Dried slides were imaged with an Olympus IX70 epiﬂuorescent
microscope ﬁtted with an automated stage (Applied Precision Inc.)
and images were captured in z-series on a CCD digital camera. Out of
focus light was digitally removed using the Softworks deconvolution
software (Applied Precision Inc.).
Immunoﬂuorescence analysis of viral transduction after transfection
with mRFP-Eps15 plasmids
HOS, HeLa, Vero and 293T cells were plated on coverslips followed
by transient transfection with dominant-negative (DN) or control
mRFP-Eps15 plasmids using Effectene transfection reagent (Qiagen).
24 h post-transfection, the cells were incubated with virus for 4 h.
48 h later, the cells were ﬁxed and the DNAwas stained with Hoechst.
The coverslips were imaged as described in the Transfection with
eGFP-clathrin followed by chlorpromazine or sucrose treatment
section. Several panels of images were collected from different
sections of the coverslips and the number of transfected cells and
transfected and infected cells in each panel was counted. A minimumof 100 transfected cells was counted in each case. The experiment was
repeated three times and the percentage of transfected and infected
cells was determined in every population for each individual
experiment.
Immunoﬂuorescence studies with TR or Fluorescein–transferrin
HOS cells were pre-incubatedwith 10 μg/ml of chlorpromazine for
2 h or 0.45 M sucrose for 45 min or a combination of 10 μg/ml of
chlorpromazine and 0.45 M sucrose for 2 h. This was followed by
incubation with 14 μg/ml of TR-transferrin for various time points. In
another experiment, HOS cells were transiently transfected with
dominant-negative or control mRFP-Eps15 plasmids. 24 h post-
transfection, the cells were incubated with 14 μg/ml of Fluorescein–
transferrin for various time points. In all the experiments, the cells
were rinsed extensively to remove any unbound transferrin, and were
ﬁxed, and the DNA was stained with Hoechst. The coverslips were
imaged as described in the Transfection with eGFP-clathrin followed
by chlorpromazine or sucrose treatment section. The ﬂuorescence
intensity settings for transferrin were equalized in the treated and
control images.
Intracellular detection of transferrin receptor by immunoﬂuorescence
HOS cells were plated on coverslips and incubated with 10 μg/ml of
chlorpromazine for 45 min or 0.45 M sucrose for 10 min. The cells were
ﬁxed and stained for transferrin receptor using mouse monoclonal
antibody against human transferrin receptor and Cy3-conjugated
secondary antibody. The DNAwas stained with Hoechst. The coverslips
were imaged as described in the Transfection with eGFP-clathrin
followed by chlorpromazine or sucrose treatment section. The ﬂuores-
cence intensity settings for transferrin receptor were equalized in the
treated and control images.
Immunoﬂuorescence study to examine transferrin endocytosis following
siRNA-mediated knockdown of clathrin
The siRNA duplex was synthesized as a 21-mer with UU overhangs
(Dharmacon). The clathrin heavy chain target sequence was GCAAU-
GAGCUGUUUGAAGA. The siRNA duplex was designed and synthe-
sized exactly as described previously (Huang et al., 2004). The siRNA
duplexwas resuspended in 1× siRNA universal buffer (Dharmacon) to
20 μM before transfection.
HOS cells were seeded on coverslips and incubated in DMEM
containing 10% FBS without antibiotics for 24 h. The cells were tran-
siently transfected twice at 24 h intervals with 4 μl of siRNA duplex,
1 μg/ml of eGFP (as a transfection marker) and 3 μl of Lipofectamine
2000 reagent (Invitrogen) in 100 μl of Opti-MEM I medium. 4 h later,
the transfection medium was replaced with regular DMEM supple-
mented with antibiotics. 48 h following the second transfection, the
cells were incubated with 14 μg/ml of TR-transferrin for 30 min. Cells
were rinsed extensively to remove any unbound transferrin, ﬁxed and
stained for clathrin usingmousemonoclonal antibody against clathrin
heavy chain (Afﬁnity Bioreagents) and Cy5-conjugated anti-mouse
secondary antibody. The coverslips were mounted onto glass slides
and imaged as described in the Transfection with eGFP-clathrin
followed by chlorpromazine or sucrose treatment section.
Western blotting to detect siRNA-mediated knockdown of clathrin
HOS cells were seeded in 12-well plates and incubated in 1 ml
media containing 10% FBS without antibiotics for 24 h. Cells were
transfected twice at 24 h intervals with 4 μl of siRNA duplex and 3 μl of
Lipofectamine 2000 reagent (Invitrogen) in 100 μl of Opti-MEM I
medium. 4 h later, the transfection medium was removed and regular
mediumwas added to the cells. 48 h after the second transfection, the
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NaCl, 10% glycerol, 1% Triton X-100, 1 mMEGTA, 1.5 mMMgCl2, 1 mM
Na-orthovanadate, 1 mM phenylmethylsulfonyl ﬂuoride, and 1×
protease inhibitor cocktail (Roche)) and then scraped off from the
plate with a polyethylene cell lifter. The protein concentration in each
lysate was measured using the DC protein assay kit (Bio-Rad). Equal
amounts of lysates were loaded onto 8% Tris–Glycine Sodium dodecyl
sulphate, polyacrylamide gel electrophoresis (SDS PAGE) gel; the
proteins were separated by SDS PAGE and then transferred to a PVDF
membrane. The blot was probed for clathrin using mouse monoclonal
antibody against clathrin heavy chain followed by detection using
enhanced chemiluminescence system (Pierce). The blots were also
probed for GAPDH as a loading control.
Immunoﬂuorescence analysis of viral transduction following
siRNA-mediated knockdown of clathrin
HOS cells were seeded on coverslips and incubated in 1 ml DMEM
containing 10% FBS without antibiotics for 24 h. The cells were
then transfected twice at 24 h intervals with 4 μl of siRNA duplex,
0.25 μg/ml mCherry plasmid (as a transfection marker) and 3 μl of
Lipofectamine 2000 reagent (Invitrogen) in 100 μl of Opti-MEM I
medium. 4 h later, the transfectionmediumwas replaced with regular
DMEM supplemented with antibiotics. 48 h following the second
transfection, the cells were incubated with virus for 4 h. Control cells
were transfected with 0.25 μg/ml mCherry plasmid and 3 μl of
Lipofectamine 2000 reagent (Invitrogen) in 100 μl of Opti-MEM I
medium. 48 h post-infection, the cells were ﬁxed and the DNA was
stained with Hoechst. The coverslips were imaged and analyzed as
described in the Immunoﬂuorescence analysis of viral transduction
after transfection with mRFP-Eps15 plasmids section. The experiment
was repeated three times and fold change in viral infectivity in siRNA-
transfected cells compared to the control cells was calculated.
Statistical analysis of experimental data
p Values were determined by comparing treated versus control
samples using a paired student t test with GraphPad InStat3 software.
For the Eps15 and clathrin siRNA experiments, p values were cal-
culated by comparing the fold decrease in EbGP mediated infectivity
with VSVg and HIV infectivity using the one way analysis of variance
(ANOVA) test.
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